Merck has committed $30 million in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop an updated version of its recombinant vesicular stomatitis virus–based Ebola vaccine aimed specifically at reducing production costs and improving distribution in low- and middle-income countries. Under the agreement, Merck will leverage its established manufacturing network—currently capable of producing more than 2 million doses per year—to optimize yield and reduce per-dose costs by at least 25 percent over the next three years. CEPI will co-fund late-stage clinical testing in West African cohorts, targeting regulatory submissions by mid-2028. This initiative not only addresses a critical unmet public-health need but also strengthens Merck’s infectious-disease pipeline, with analysts projecting that expanding vaccine access could drive incremental annual revenues of $150 million by 2030 while securing new procurement contracts with Gavi and WHO prequalification for broader market penetration.

Merck’s co-development of a personalized mRNA cancer vaccine with Moderna demonstrated sustained clinical benefit in high-risk, resected stage III/IV melanoma, reducing the risk of recurrence or death by 49 percent versus standard pembrolizumab monotherapy at median five-year follow-up. The Phase 2b KEYNOTE-942 study enrolled 157 patients across 25 centers and reported a 60 percent three-year recurrence-free survival (RFS) rate for the combination arm compared to 42 percent for pembrolizumab alone. Safety profiles remain consistent, with grade 3/4 adverse events observed in 18 percent of patients—comparable to control. Merck and Moderna will present comprehensive primary and secondary endpoint analyses at the upcoming ASCO conference in June 2026. Given an estimated annual incidence of 112,000 melanoma cases in the U.S. and a potential list price near $200,000 per treatment, analysts forecast peak annual sales for the melanoma indication alone could exceed $2 billion. The five-year durability data underpin Merck’s broader strategy to expand its immuno-oncology portfolio and may catalyze additional alliances in kidney, bladder and lung cancer indications.